Allakos Inc ALLK:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
1.20UNCH (UNCH)
Volume
4,793
Close
1.20quote price arrow down-0.09 (-6.98%)
Volume
518,993
52 week range
0.98 - 5.64
Loading...
  • Open1.21
  • Day High1.24
  • Day Low1.17
  • Prev Close1.29
  • 52 Week High5.64
  • 52 Week High Date08/07/23
  • 52 Week Low0.98
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap106.253M
  • Shares Out88.54M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change-56.04

KEY STATS

  • Open1.21
  • Day High1.24
  • Day Low1.17
  • Prev Close1.29
  • 52 Week High5.64
  • 52 Week High Date08/07/23
  • 52 Week Low0.98
  • 52 Week Low Date04/25/24
  • Market Cap106.253M
  • Shares Out88.54M
  • 10 Day Average Volume0.42M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change-56.04

RATIOS/PROFITABILITY

  • EPS (TTM)-2.45
  • P/E (TTM)-0.49
  • Fwd P/E (NTM)-1.01
  • EBITDA (TTM)-189.915M
  • ROE (TTM)-77.50%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Allakos Inc

 

Profile

MORE
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially...
Daniel Janney
Independent Chairman of the Board
Robert Alexander Ph.D.
Chief Executive Officer, Director
Adam Tomasi Ph.D.
President
Baird Radford
Chief Financial Officer
Address
825 INDUSTRIAL ROAD, SUITE 500
San Carlos, CA
94070
United States

Top Peers

SYMBOLLASTCHG%CHG
OTLK
Outlook Therapeutics Inc
7.58-0.15-1.94%
GNLX
Genelux Corp
3.83-0.19-4.73%
PMVP
PMV Pharmaceuticals Inc
2.04-0.06-2.86%
IOBT
IO Biotech Inc
1.43-0.15-9.49%
ANIX
Anixa Biosciences Inc
3.00+0.13+4.53%